Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%

Skin Pharmacology and Physiology

Volumn 25, Issue 3, 2012, Pages 133-141

  Korting, H C ^a   Schollmann C ^a   Willers, C ^b   Wigger Alberti, W ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Almirall Hermal   (Germany)

^c Bioskin GmbH   (Germany)

Author keywords

Light cream; Mometasone furoate; Psoriasis plaque test; Vasoconstriction assay

Indexed keywords

CLOBETASOL PROPIONATE; MOMETASONE FUROATE; MONOVO; TOLNAFTATE; TRIAMCINOLONE ACETONIDE; TRIAMGALEN; UNCLASSIFIED DRUG; WATER;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREAM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN INFILTRATE;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; GERMANY; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PREGNADIENEDIOLS; PSORIASIS; SKIN; SKIN ABSORPTION; VASOCONSTRICTION; YOUNG ADULT;

EID: 84857132896     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000335656     Document Type: Article

References (30)

1. Korting HC, Kerscher M, Schäfer-Korting M: Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol 1992; 27: 87-92
2. Surber C, Itin PH, Bircher AJ, Maibach HI: Topical corticosteroids. J Am Acad Dermatol 1995; 32: 1025-1030
3. Hughes J, Rustin M: Corticosteroids. Clin Dermatol 1997; 15: 715-721 (Pubitemid 27411305)
4. Korting HC, Hülsebus E, Kerscher M, Greber R, Schäfer-Korting M: Discrimination of the toxic potential of chemically differing topical glucocorticoids using a neutral red release assay with human keratinocytes and fibroblasts. Br J Dermatol 1995; 133: 54-59
5. Proksch E: The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol. 2008; 21: 75-80 (Pubitemid 351440525)
6. Braun-Falco O, Plewig G, Wolff HH: Dermatologie und Venerologie, ed 4. Berlin, Springer, 2002
7. Kerscher MJ, Hart H, Korting HC, Stalleicken D: In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 1995; 33: 187-189
8. Kulhalli P, Chevli T, Karnik R, Sheth M, Mulgaonkar N: Comparative potency of formulations of mometasone furoate in terms of inhibition of 'PIRHR' in the forearm skin of normal human subjects measured with Laser Doppler Velocimetry. Indian J Dermatol Venereol Leprol 2005; 71: 170-174 (Pubitemid 40898200)
9. Prakash A, Benfield P: Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998; 55: 145-163 (Pubitemid 28035129)
10. Luger TA: Topische Dermatotherapie mit Glukokortikoiden; in Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (eds): Dermatologische Qualitätssicherung, vol 6. Leitlinien und Empfehlungen. Berlin, ABW Wissenschaftsverlag, 2009, pp 943-951
11. Wiedersberg S, Leopold CS, Guy RH: Bioavailability and bioequivalence of topicalglucocorticoids. Eur J Pharm Biopharm 2008; 68: 453-466
12. Olsen EA: A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay. Arch Dermatol 1991; 127: 197-201
13. Ayres JW, Hooper G: Assessment of the skin penetration properties of different carrier vehicles for topically applied cortisol. Br J Dermatol 1978; 99: 307-317 (Pubitemid 9008787)
14. Poulsen J, Rorsman H: Ranking of glucocorticoid creams and ointments. Acta Derm Venereol 1980; 60: 57-62 (Pubitemid 10201658)
15. Korting HC: Influence of glucocorticoid substances and the vehicle on skin irritancy: determination by profilometry. Curr Probl Dermatol 1993; 21: 140-146
16. Sequira J, Berardi M, Chan TM, Letarte J, Malchow R, Pramanick B, Wolkoff HN: Assessing equivalence of innovator and generic formulations of betamethasone dipropionate cream and ointment. Clin Ther 1991; 13: 687-694
17. Korting HC, Maslen K, Gross G, Willers C: Vergleich der Wirksamkeit verschiedener topischer Glukokortikoidcremes und -salben im Vasokonstriktionstest: Überlegenheit von Hydrocortisonbutyrat gegenüber Hydrocortison. J Dtsch Dermatol Ges 2005; 3: 348-353 (Pubitemid 40754641)
18. Kirkland R, Pearce DJ, Balkrishnan R, Feldman SR: Critical factors determining the potency of topical corticosteroids. J Dermatol Treat 2006; 17: 133-135 (Pubitemid 44147828)
19. Haigh JM, Kanfer I: Assessment of topical corticosteroid preparations: the human skin blanching assay. Int J Pharm 1984; 19: 245-262 (Pubitemid 14120841)
20. Brown PH, Teeluckisingh S, Matusiewicz SP, Greening AP, Crompton GK, Edwards CRW: Cutaneous vasoconstrictor response to glucocortisteroids in asthma. Lancet 1991; 337:576-580
21. Borelli C, Gassmueller J, Fluhr JW, Nietsch KH, Schinzel S, Korting HC: Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay. Skin Pharmacol Physiol 2008; 21: 181-187 (Pubitemid 351793746)
22. Cornell RC: Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay. Int J Dermatol 1992; 31(suppl 1):38-40
23. Dumas KJ, Scholtz JR: The psoriasis bio-assay for topical corticosteroid activity. Acta Derm Venereol 1972; 52: 43-48
24. Dumas KJ, Scholtz JR: Psoriasis-Plaque Test; in Wendt H, Frosch PJ (eds): Clinico-Pharmacological Models for the Assay of Topical Corticoids. Basel, Karger, 1982, pp 31-35
25. Koivukangas V, Karvonen J, Risteli J, Oikarinen A: Topical mometasone furoate andbetamethasone-17- valerate decrease collagen synthesis to a similar extent in human skin in vivo. Br J Dermatol 1995; 132: 66-68
26. Wilkinson SM, Beck MH: Fluticasone propionate and mometasone furoate have a low risk of contact sensitization. Contact Dermatitis 1996; 34: 365-366 (Pubitemid 26193440)
27. Hoffmann K, Auer T, Stücker M, Hofmann A, Altmeyer P: Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol 1998; 10: 137-142 (Pubitemid 28137574)
28. Medansky RS, Bressinck R, Cole GW, Deeken JH, Ellis CN, Guin JD, Herndon JH, Lasser AE, Leibsohn E, Menter MA, et al: Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone actinide 0.025 percent and triamcinolone acetonide 0.1 percent. Cutis 1988; 42: 480-485 (Pubitemid 19005569)
29. Katz HI, Prawer SE, Watson MJ, Scull TA, Peets EA: Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. Atrophogenic potential. Int J Dermatol 1989; 28: 342-344 (Pubitemid 19179645)
30. Faergemann J, Christensen O, Sjövall P, Johnssson A, Hersle K, Nordin P, Edmar B, Svensson A: An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2000; 14: 393-396 (Pubitemid 32898894)